As of June 6, 2025, Vistin Pharma ASA (VISTN.OL) reports a ROA (Return on Assets) of 11.30%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Vistin Pharma ASA's ROA (Return on Assets)
Over recent years, Vistin Pharma ASA's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 11.30% |
| 2023-12-31 | 11.30% |
| 2022-12-31 | -1.16% |
| 2021-12-31 | 7.46% |
| 2020-12-31 | -30.12% |
This fluctuation highlights how Vistin Pharma ASA manages its efficiency in using assets to generate earnings over time.
Comparing Vistin Pharma ASA's ROA (Return on Assets) to Peers
To better understand Vistin Pharma ASA's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Vistin Pharma ASA (VISTN.OL) | 11.30% |
| Acacia Pharma Group PLC (ACPH.BR) | 172.79% |
| Oncoarendi Therapeutics SA (OAT.WA) | 41.87% |
| Shedir Pharma Srl Unipersonale (SHE.MI) | 10.15% |
| Lavipharm SA (LAVI.AT) | 7.16% |
| Nutex Befektetesi Nyrt (NUTEX.BD) | 3.12% |
Compared to its competitors, Vistin Pharma ASA's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.